Back9 Meters Biopharma Overview

9 Meters Biopharma Operating Income

9 Meters Biopharma's operating income is $-43M.

Get informed when a big investor buys or sells

+ Follow

Quarterly Operating Income

-$12.79M
↓ 12.52% YoY

As of Mar 31, 2023

Annual Operating Income (TTM)

-$43.44M
↓ 1.67% YoY

Trailing 12 months ending Mar 31, 2023

Average Operating Income (Comparison Companies)

Operating Income History

Operating Income Comparison

Annual Operating Income Growth Rate (%)

Annual Operating Income Growth (Absolute)

9 Meters Biopharma (NMTRQ) FAQ

The latest operating income for NMTRQ is $-43M as of March 2023. That compares with $-43M in the prior-year period — down 1.7% year over year. Investors often review this figure alongside 9 Meters Biopharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, NMTRQ's operating income moved from $-43M to $-43M — a 1.7% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in 9 Meters Biopharma's operating scale or balance-sheet position.

A operating income figure of $-43M for NMTRQ is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting NMTRQ's operating income ($-43M), review year-over-year change from $-43M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack 9 Meters Biopharma's operating income against similar Technology names. You can also browse sector and industry screens on Stockcircle for a broader set of Technology companies and their key multiples and fundamentals.